NasdaqCM - Nasdaq Real Time Price USD

Cerevel Therapeutics Holdings, Inc. (CERE)

42.07 +0.17 (+0.41%)
At close: April 25 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. N. Anthony Coles Jr., M.P.H. Executive Chairman 1.14M -- 1960
Mr. Mark Bodenrader VP of Finance & Chief Accounting Officer 496.17k -- 1973
Dr. John J. Renger Ph.D. Chief Scientific Officer 779.75k 10.44M 1969
Dr. Ramiro Sanchez M.D. Chief Medical Officer 805.13k -- 1961
Mr. Ronald C. Renaud Jr., M.B.A. President, CEO & Director -- -- 1969
Dr. Susan Altschuller M.B.A., Ph.D. Chief Financial Officer -- -- 1982
Mr. Matthew Calistri Vice President of Investor Relations -- -- --
Mr. Scott M. Akamine J.D. Chief Legal Officer & Corporate Secretary 444.74k -- 1985
Mr. Kenneth A. DiPietro Chief Human Resources Officer -- -- 1959
Ms. Kathleen Tregoning M.A. Chief Corporate Affairs Officer 600.79k -- 1971

Cerevel Therapeutics Holdings, Inc.

222 Jacobs Street
Suite 200
Cambridge, MA 02141
United States
844 304 2048 https://www.cerevel.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
334

Description

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, develops various therapies for neuroscience diseases in the United States. It is developing Emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures or focal epilepsy, as well as in phase 1 trial to treat panic symptoms model. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; and CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and PDE4 inhibitor for the treatment of psychiatric, neuroinflammatory, and other disorders. Cerevel Therapeutics Holdings, Inc. was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Cerevel Therapeutics Holdings, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 6. The pillar scores are Audit: 8; Board: 7; Shareholder Rights: 5; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 01, 2024 - May 06, 2024
Cerevel Therapeutics Holdings, Inc. Earnings Call

Related Tickers

FUSN Fusion Pharmaceuticals Inc.
21.40
0.00%
 
TNGX Tango Therapeutics, Inc.
7.33
-5.54%
 
IGMS IGM Biosciences, Inc.
7.65
-3.89%
 
CYTK Cytokinetics, Incorporated
64.80
-3.02%
 
ALPN Alpine Immune Sciences, Inc.
64.62
+0.08%
 
SWTX SpringWorks Therapeutics, Inc.
44.20
+1.89%
 
EWTX Edgewise Therapeutics, Inc.
15.94
-1.06%
 
BGNE BeiGene, Ltd.
148.56
+3.08%
 
RVMD Revolution Medicines, Inc.
35.33
-0.73%
 
PSTX Poseida Therapeutics, Inc.
2.0500
-0.97%